Abpro Holdings, Inc. (ABPO)
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Abpro Holdings, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 0.4900 | 0.5337 | 0.4500 | 0.5337 | 23,295 |
| Nov 13, 2026 | 0.5530 | 0.5600 | 0.4700 | 0.5300 | 2,266 |
| Nov 12, 2026 | 0.5100 | 0.6273 | 0.4510 | 0.5100 | 25,847 |
| Nov 11, 2026 | 0.4050 | 0.5799 | 0.4050 | 0.5363 | 17,504 |
| Nov 10, 2026 | 0.5000 | 0.5000 | 0.4125 | 0.4990 | 17,723 |
| Nov 9, 2026 | 0.4700 | 0.5800 | 0.4700 | 0.5513 | 1,732 |
| Nov 6, 2026 | 0.5627 | 0.6200 | 0.4410 | 0.5775 | 26,620 |
| Nov 5, 2026 | 0.4450 | 0.5750 | 0.4450 | 0.5600 | 6,171 |
| Nov 4, 2026 | 0.3751 | 0.5300 | 0.3751 | 0.5000 | 12,056 |
| Nov 3, 2026 | 0.4600 | 0.4838 | 0.4050 | 0.4838 | 4,331 |
| Nov 2, 2026 | 0.4497 | 0.4500 | 0.4432 | 0.4432 | 7,154 |
| Oct 30, 2026 | 0.3975 | 0.4364 | 0.3900 | 0.4364 | 17,203 |
| Oct 29, 2026 | 0.3999 | 0.4273 | 0.3999 | 0.4273 | 3,602 |
| Oct 28, 2026 | 0.4000 | 0.4310 | 0.3800 | 0.4310 | 91,998 |
| Oct 27, 2026 | 0.4025 | 0.4050 | 0.3700 | 0.3910 | 7,474 |
| Oct 26, 2026 | 0.3650 | 0.4350 | 0.3645 | 0.3912 | 47,065 |
| Oct 23, 2026 | 0.3761 | 0.4212 | 0.3656 | 0.4212 | 4,287 |
| Oct 21, 2026 | 0.3900 | 0.4250 | 0.3900 | 0.4005 | 20,079 |
| Oct 20, 2026 | 0.3557 | 0.3900 | 0.3557 | 0.3900 | 5,370 |
| Oct 19, 2026 | 0.3570 | 0.4081 | 0.3570 | 0.4081 | 548 |
| Name | Shares | % | Source |
|---|---|---|---|
Abpro Bio International, Inc. 10% Owner | 16.5M | -- | FORM 4 |
Chan Ian Chief Executive Officer, Director, 10% Owner | 6.5M | -- | FORM 4 |
Suk Jin Wook (Miles) Co-CEO & Chairman, Director | 718.5K | 12.2% | FORM 4 |
Sandia Investment Management LP ABPWW | 358.4K | -- | 13F |
THE GOLDMAN SACHS GROUP, INC. · joint filing· may incl. warrants· filed Sep 2026 | 180.7K | 3.1% | 13G |
VANGUARD GROUP INC | 20.1K | 0.3% | 13F |
Insiders
- Abpro Bio International, Inc.10% Owner
- Chan IanChief Executive Officer, Director, 10% Owner
- Suk Jin Wook (Miles)Co-CEO & Chairman, Director
Top institutional holders
Abpro Holdings, Inc. is a biotechnology firm specializing in the creation of innovative antibody treatments, primarily targeting immuno-oncology and ophthalmology.
The company leverages two proprietary technological platforms: DiversImmune, a discovery platform that identifies a broad spectrum of unique antibodies against both established and emerging therapeutic targets, and MultiMab, an engineering platform offering the versatility to assemble antibody components into customized, multi-specific constructs tailored for specific therapeutic needs. Abpro's flagship therapeutic pipeline includes ABP-102, a next-generation immuno-oncology TetraBi antibody engineered to dually target HER2 and CD3, offering a potential treatment for HER2-positive solid tumors like breast and gastric cancers. Another key candidate, ABP-201, is a TetraBi antibody designed to simultaneously inhibit both VEGF and ANG-2 pathways for the management of vascular eye diseases, such as diabetic macular edema and wet age-related macular degeneration.
The company's pipeline also features ABP-110, a TetraBi antibody targeting GPC3 and CD3 for hepatocellular carcinoma, and ABP-150, another TetraBi antibody focused on claudin 18.2 and CD3 for gastric cancers. Abpro maintains strategic alliances with Celltrion Inc. and Abpro Bio International, Inc. Established in 2004, Abpro Holdings, Inc. is headquartered in Woburn, Massachusetts.
based on 5.90M shares outstanding
30d Avg
17.12K
60d Avg
11.83K
90d Avg
17.62K
Signal8's dilution snapshot of ABPO as of Jun 30, 2026 records 3 outstanding warrant series and an offering closed Nov 7, 2025, from SEC filings. Abpro Holdings, Inc. (OTC: ABPO) traded at $0.5337 on Nov 17, 2026, up 0.70% from the previous close of $0.5300. 52-week range: $0.0866 to $7.34. The company is in the Healthcare sector (Biotechnology).